---
title: "Jupiter Neurosciences climbs 5% on $100M ALA-002 licensing deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293378582.md"
description: "Jupiter Neurosciences rose 5% during regular trading after securing US rights to neuroprotective candidate ALA-002 in a deal worth up to $100M."
datetime: "2026-07-21T19:40:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293378582.md)
  - [en](https://longbridge.com/en/news/293378582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293378582.md)
generator: "portal-rs"
---

# Jupiter Neurosciences climbs 5% on $100M ALA-002 licensing deal

Jupiter Neurosciences(JUNS.US) 盘中涨 4.55%，现报 0.1725 美元。

消息面上，公司获得神经保护候选药物 ALA-002 的美国权利，该授权协议总价值达 1 亿美元。

### Related Stocks

- [JUNS.US](https://longbridge.com/en/quote/JUNS.US.md)

## Related News & Research

- [Jupiter Neurosciences Prices $2.0 Million Registered Direct Offering at $6.50 Per Share](https://longbridge.com/en/news/296786477.md)
- [Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | JUNS Stock News](https://longbridge.com/en/news/296638594.md)
- [PharmAla net loss narrows to CAD 499,759 in Q3 FY26; revenue more than doubled to CAD 513,000](https://longbridge.com/en/news/294356612.md)
- [Jupiter Neurosciences FY26 Q2 net loss widens 0.95% to $2.27 million; revenue totals $24,245](https://longbridge.com/en/news/295975039.md)
- [Jupiter Neurosciences Delays Annual 10-K Filing](https://longbridge.com/en/news/281440517.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**